



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jacques DUMAS et al.

Confirmation No.: 8328

Serial No.: 09/458,014

Examiner: MITCHELL, Gregory W.

Filed: December 10, 1999

Group Art Unit: 1617


Title: INHIBITION OF P38 KINASE USING ACTIVITY SUBSTITUTED
HETEROCYCLIC UREAS

REPLY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In response to the Office Action dated November 30, 2005, applicants elect with traverse as a single disease rheumatoid arthritis and as a single compound the following compound



The traversal is on the basis that the PTO has not established that it would pose an undue burden to examine the full scope of the application.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,


Csaba Henter, Reg. No. 50,908
Richard J. Traverso, Reg. No. 30,595
Attorneys for Applicants

MILLEN, WHITE, ZELANO &
BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER-0011-C01

Date: February 1, 2006